Complete resolution of primary cutaneous marginal zone B‐cell lymphoma on the cheek of a 7‐year‐old boy with intralesional triamcinolone and tincture of time

Abstract

A 7-year-old healthy boy presented with an asymptomatic smooth, firm red plaque on the cheek. Histopathology, immunostaining, molecular testing and imaging confirmed a diagnosis of a primary cutaneous marginal zone B-cell lymphoma. The lesion was treated with intralesional triamcinolone, with complete clinical resolution achieved within one year. Intralesional steroid injection is an effective first-line modality for the treatment of patients with limited disease in cosmetically sensitive areas.

Rare non‐Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric‐type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T‐cell lymphoma

“…7,38,[51][52][53][54] Pediatric eMZL has also been described in the orbita, skin, breast, spleen, kidney, and CNS. 7,36,42,49,53,55,56 In order to gain further information in MZL, the EICNHL and i-BFM Group performed a retrospective multinational study by which we identified 66 patients with MZL and added relevant data to the few case reports and series of MZL in childhood and adolescence reported up till then. 7 pnMZL shows a clear male predominance and is most commonly diagnosed in adolescents (Table 2).…”

“…Data on clinical features, treatment, and outcome of MZL in children and adolescents are limited to a few reports on small patient series and several case reports that have been published to date. 7,10,[36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] As therapy guidelines for childhood MZL have not yet been defined, treatment for both localized and disseminated disease varies considerably. 10,45,50…”

“…Since the introduction of pediatric nodal MZL (pnMZL) as a variant of MZL in 2008, the incidence of MZL diagnoses reported in children, adolescents, and young adults has significantly increased, but the overall incidence among childhood NHL still seems to be <2%. Data on clinical features, treatment, and outcome of MZL in children and adolescents are limited to a few reports on small patient series and several case reports that have been published to date 7,10,36‐53 . As therapy guidelines for childhood MZL have not yet been defined, treatment for both localized and disseminated disease varies considerably 10,45,50 …”

“…In contrast, pediatric eMZL frequently manifests at sites of mucosa‐associated tissues such as salivary glands, the ear‐nose‐throat area, lungs, digestive tract, and conjunctiva or ocular adnexa 7,38,51‐54 . Pediatric eMZL has also been described in the orbita, skin, breast, spleen, kidney, and CNS 7,36,42,49,53,55,56 . In order to gain further information in MZL, the EICNHL and i‐BFM Group performed a retrospective multinational study by which we identified 66 patients with MZL and added relevant data to the few case reports and series of MZL in childhood and adolescence reported up till then 7 …”

Pediatric Primary Cutaneous Marginal Zone Lymphoma Treated With Doxycycline

“…Treatment options include radiation therapy, excision, topical steroids, intralesional steroids, intralesional rituximab, and antibiotics. 2,[12][13][14] Case reports of pediatric patients have demonstrated improvement with excision, [15][16][17][18][19] intralesional steroids, 20,21 intralesional rituximab, 22 and clobetasol cream. 23,24 In asymptomatic patients, watchful waiting often is employed given the overall indolent nature of PCMZL.…”